Transcatheter Mitral Valve Replacement Attracts Interest From Edwards, Others
This article was originally published in The Gray Sheet
Executive Summary
Leading the development of transcatheter mitral valve replacement therapies is one of Edwards Lifesciences’ strategic imperatives, the company explained during its recent investor conference. The potential market is large, but so are the technical hurdles. Medtronic and other smaller players are also taking steps.
You may also be interested in...
Neovasc Sees Opportunities In Refractory Angina And Mitral Regurgitation Markets
Neovasc Inc. is targeting two highly underserved markets in cardiology – refractory angina and mitral valve disease – with unique transcatheter solutions. The angina device, called the Neovasc Reducer, is expected to enter the European market early next year.
FDA Advisors Vote That Benefits Of Abbott’s MitraClip Outweigh Risks
The agency’s Circulatory System Devices Panel narrowly voted in favor of Abbott’s MitraClip transcatheter mitral valve repair system to reduce mitral regurgitation. But the discussions about the clinical evidence on the technology were complex and the panel’s support for Abbott’s PMA was not unanimous.
Cell/Gene Therapy Is Ripe For Real-World Data Given Length Of Follow-Up Required, Abernethy Says
The former principal deputy commissioner outlined what she sees as the future data requirements for real world evidence and why cell and gene therapy will lead the way.